Skip to main content

AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M

The global licensing deal also includes exclusive rights for other undisclosed inflammatory and respiratory diseases.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.